Lipomatous tumours in adrenal gland: WHO updates and clinical implications

Alfred King-yin Lam
Cancer Molecular Pathology, Menzies Health Institute Queensland and School of Medicine, Griffith University, Gold Coast, Australia

Abstract

Adrenal lipomatous tumour is a group of adrenal tumours with a significant component of adipose tissue. According to the current World Health Organization (WHO) classification of tumours of endocrine organs, adrenal myelolipoma is the only entity amongst the group of tumours being described. In the literature, other more recently documented adrenal lipomatous tumours included 24 lipomas, 32 teratomas and 16 angiomyolipomas. Rare fatty tumours of the adrenal gland comprised liposarcoma, hibernoma, adrenocortical tumours with fat component and rare adrenal tumours with fat component. Myelolipoma comprises approximately 3% of primary adrenal tumour. It is noted more commonly in females and in the right adrenal gland. Approximately 40 bilateral myelolipomas were reported. The tumour is most frequently recorded in patients between fifth and seventh decades of life. Adrenal lipomas are often seen in males and in the right adrenal gland. They were commonly noted in patients in the sixth decade of life. The diagnosis could only be possible on examination of the surgically removed specimen. Adrenal teratomas were more common in females and with a bimodal age distribution. Slightly over 60% of the patients with adrenal teratoma are symptomatic. Adrenal angiomyolipomas were often symptomatic, more common in females and in the fifth decades of life. To conclude, adrenal lipomatous tumour is uncommon. They are often benign and non-functional. It is important to recognize the features of this group of lipomatous tumours in the adrenal gland as they are being detected on increasing incidence as a result of the wide-spread use of modern imaging modalities.

Introduction

Adrenal lipomatous tumour is defined as a group of adrenal tumours with a significant proportion of adipose tissue. Only two large series of adrenal lipomatous tumours were noted in the literature (Lam & Lo 2001, Zhao et al. 2014). In the past, adrenal lipomatous tumours were often detected at autopsy. In the recent years, they were detected as fat-containing adrenal incidentaloma by ultrasonography, computerized tomography (CT) or magnetic resonance imaging (MRI) as well as functional imaging such as positron emission tomography (PET).

Myelolipoma is the most common type of adrenal lipomatous tumours. In the 4th edition of World Health Organization (WHO) classification of tumours of endocrine organs, adrenal myelolipoma is the only entity amongst the group of tumours being described (Lam et al. 2017). Apart from adrenal myelolipomas, there is lack of information of the other adrenal lipomatous tumours. These adrenal lipomatous tumours were often reported as case reports in the literature. They are relatively recently described in the literature when compared to myelolipoma. To date, there

Key Words

- lipomatous
- adrenal
- myelolipoma
- lipoma
- teratoma
- angiomyolipoma

Correspondence should be addressed to A K-y Lam
Email a.lam@griffith.edu.au
is no review in literature on this group of adrenal tumours in the literature. In this review, the currently available data on the epidemiological, clinical and pathological aspects of this group of adrenal disease were presented. Particular emphases were put on the adrenal lipomatous tumours other than myelolipomas as they have not been covered in the current WHO classification.

**Myelolipoma**

The most well-known adrenal lipomatous tumour is adrenal myelolipoma. Myelolipoma is the second most common adrenocortical tumour and the most common adrenal lipomatous tumour (Lam 1992, Lam & Lo 2001). It is a benign tumour in the adrenal cortex composed of mixture of adipose tissue and bone marrow (haematopoietic) elements. In large series, adrenal myelolipoma comprises approximately 3–4% of primary adrenal tumour (Lam & Lo 2001, Kulis et al. 2012, Shenoy et al. 2015).

In 2017s edition of World Health Organization (WHO) classification of tumours of endocrine organs, adrenal myelolipoma is classified as mesenchymal and stroma tumour in the adrenal cortex (Lam et al. 2017). In this edition, when compared to the previous edition, the epidemiology, localization, clinical features, macroscopy, histopathology, genetic profile, prognostic and predictive factors of the tumour were updated. These updates were included in the following sections.

In the literature, Arnold recorded the earliest documented case of adrenal myelolipoma as ‘adrenal lipoma’ in German literature in 1866 (Arnold 1866). Then, Edgar von Gierke, a German pathologist, reported the fatty component and myeloid component in 1905 (Gierke 1905). The name ‘myelolipoma’ was first coined by 1929 by a French pathologist, Charles Oberling (Oberling 1929).

The fat component of adrenal myelolipoma was postulated to be derived by the mesenchymal stem cells of stromal fat of adrenal cortex (Feng et al. 2013). The mature adipocytes then stimulate factors to recruit circulating haematopoietic elements to the site.

The metaplasia occurs in response to stress related to stimuli such as necrosis, infection, stress or trauma. The stress may be related to prolong increase in endogenous adrenocorticotropic hormone (ACTH) stimulation (Shenoy et al. 2015). Myelolipoma has been reported to be associated with many diseases as it was commonly being detected incidentally during workup for other diseases. In some adrenal myelolipomas, they were detected in patients with chronic diseases such as cancers and diabetes mellitus. In these conditions, endogenous ACTH could be elevated. It is of interest that some adrenal myelolipomas were associated with haematological diseases in which haemolytic anaemia or ineffective erythropoiesis is present (Au et al. 2000, Motta et al. 2016). These haematological conditions could contribute to the presence of extramedullary haematopoiesis that was postulated to trigger the myeloid component in adrenal myelolipoma.

More than 1200 cases of adrenal myelolipomas were reported in the literature with more than 75% of the cases reported after 2000 (Shenoy et al. 2015). The increase in incidence of reporting the entity in the recent years is assumed to be due to the increased use of imaging modalities. Adrenal myelolipomas have been reported in a few larger series (Table 1) (Lam & Lo 2001, Castillo et al. 2007, Gershuni et al. 2014, Yin et al. 2014, Zhao et al. 2014). The tumour is more commonly reported in females (Table 1) (Yin et al. 2014, Zhao et al. 2014). It is most often noted in patients between fifth and seventh decades of life with an average age at presentation in the sixth decade of life. There is a wide age range at presentation from 16 months to 84 years (Lam & Lo 2001, Hsu et al. 2012,

<table>
<thead>
<tr>
<th>Author/year/country</th>
<th>Period (year)</th>
<th>No</th>
<th>Sex ratio</th>
<th>Age (range) (year)</th>
<th>Side</th>
<th>Size (mm)</th>
<th>Weight (g)</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lam/2001/HK</td>
<td>30</td>
<td>11</td>
<td>8M:3F</td>
<td>62 (41–81)</td>
<td>6R:SL</td>
<td>43 (4–145)</td>
<td>141 (4–1018)</td>
<td>Sym. = 1; Asym. = 10</td>
</tr>
<tr>
<td>Castillo/2007/Chile</td>
<td>7</td>
<td>18</td>
<td>12M:6F</td>
<td>54 (35–75)</td>
<td>16R:2L</td>
<td>86 (45–140)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Gershuni/2014/USA</td>
<td>17</td>
<td>16</td>
<td>6M:10F</td>
<td>54 (33–76)</td>
<td>7R:9L</td>
<td>84 (25–210)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Zhao/2014/China</td>
<td>31</td>
<td>65</td>
<td>21M:44F</td>
<td>52</td>
<td>41R:22L:2B</td>
<td>62</td>
<td>33.5 (15.5–1750)</td>
<td>Sym. = 53; Asym. = 12</td>
</tr>
<tr>
<td>Yin/2014/China</td>
<td>10</td>
<td>40</td>
<td>15M:25F</td>
<td>53</td>
<td>31R:9L</td>
<td>50</td>
<td>–</td>
<td>Pain = 17; no pain = 23</td>
</tr>
<tr>
<td>Total</td>
<td>150</td>
<td>62M:88F</td>
<td>–</td>
<td>101R:47L:2B</td>
<td>–</td>
<td>–</td>
<td>71 symptomatic; 45 asymptomatic</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>53 (33–81)</td>
<td>–</td>
<td>63 (4–210)</td>
<td>49 (4–175)</td>
<td>–</td>
</tr>
</tbody>
</table>

Asym., asymptomatic; f, female; L, left; M, male; R, right; Sym., symptomatic; –, not available.

The mature adipocytes then stimulate factors to recruit circulating haematopoietic elements to the site.
Barman et al. 2014). Also, it is twice more frequently seen in right adrenal gland as compared to the left (Table 1).

In the English literature, approximately 40 cases of bilateral myelolipomas were noted (Jung et al. 2007, Yang et al. 2015, Zattoni et al. 2015, Kale et al. 2015, Chakraborty et al. 2016, Soveid & Rais-Jalali 2016). Shenoy and coworkers analysed the literature and reported that 12% of cases reported in the literature are bilateral (Shenoy et al. 2015). This may be related to the bias in reporting cases of bilateral myelolipomas. From the pooled results of some large series in the literature, approximately 1% of adrenal myelolipomas were bilateral (Table 1). Recently, Zattoni and coworkers have reviewed the literature of bilateral adrenal myelolipomas (Zattoni et al. 2015). The authors noted that the average age of the 19 patients with bilateral adrenal myelolipomas was 46 years (range 24–69) with an equal sex ratio (9 males and 10 females). Bilateral adrenal myelolipomas often associated with hormonal dysfunctions such as in congenital adrenal hyperplasia, Cushing disease (with pituitary adenoma) and hyperaldosteronism (Jung et al. 2007, Kale et al. 2015, Chakraborty et al. 2016, Soveid & Rais-Jalali 2016).

On review of the literature, Shenoy and coworkers reported that adrenal myelolipoma comprised 6% of adrenal incidentaloma detected on radiological examination (Shenoy et al. 2015). For the symptomatic cases, the symptoms reported are often abdominal pain or discomfort. Occasionally, adrenal myelolipoma may present with symptoms and signs of acute abdomen as a consequence of complications (e.g. haemorrhage, rupture and abscess) (Kumar et al. 2015).

Biochemically, majority of the adrenal myelolipomas were non-functional. In the literature, endocrine dysfunction was noted in 7% of adrenal myelolipoma (Shenoy et al. 2015). A couple of cases were associated with hormonal manifestations such as excessive steroid (Cushing's syndrome), aldosterone (Conn's syndrome), sex hormones and catecholamines secretions (Tamidari et al. 2006, Udupa et al. 2012, Su et al. 2014, Shenoy et al. 2015). The hormonal manifestations disappeared after resection of these myelolipomas. The cause of the hypersecretion is largely unknown but may be due to mechanical irritation of the adrenal myelolipoma. Also, hyperthyroidism was noted in 51-year-old woman with adrenal myelolipoma (Ide et al. 2007). In this case, the cells in the myelolipoma expressed thyroid hormone receptor. In addition, many myelolipomas are noted in patients with congenital adrenal hyperplasia (Soveid & Rais-Jalali 2016). The condition accounted for nearly half of the adrenal myelolipomas with endocrine dysfunction (Shenoy et al. 2015). The aetiology could be secondary to chronic stimulation of the adrenals by adrenocorticotropic hormone (ACTH).

Radiological examination of adrenal myelolipoma reveals a hypodense mass consistent with the presence of adipose tissue (Fig. 1A). Pre-operative diagnosis could be obtained by fine needle aspiration. The presence of cells of myeloid series with interspersed adipocytes in fine needle aspiration could make a tentative diagnosis of myelolipoma (Settakorn et al. 1999, Hasan et al. 2008).

Adrenal myelolipoma is a well-demarcated cortical tumour, which is yellow to red depending on the relative proportion of the fat and hematopoietic components. The mean maximum dimension of the adrenal myelolipoma in the large ranges from 40 to 60 mm (Lam & Lo 2001, Zhao et al. 2014). From the pooled data of some large series in the literature, the mean maximum dimension of the tumour was 63 mm (Table 1). The tumour could be very big. The largest adrenal myelolipoma was reported by Lamont and coworkers in the right adrenal gland of a 50-year-old man, which is 400 mm in diameter and...
having a weight of 4254 g (Lamont et al. 2002). Also, the case reported by Akamatsu and coworkers in the left adrenal gland of a 51-year-old man weighed 6000 g (310 mm), which is the heaviest adrenal myelolipoma reported (Akamatsu et al. 2004).

On histological examination, myelolipoma is composed of mature adipocytes and bone marrow (haematopoietic elements) (Fig. 1B). The latter means may consist of different cells of myeloid (white blood cell-forming), erythroid (red blood cell forming) and megakaryocytic (platelet forming) lines. Calcification was noted in 30% of adrenal myelolipoma (Kenney et al. 1998). Heterotopic bones have been reported in a few adrenal myelolipomas (Mitsui et al. 2014). Differential diagnoses include other less common lipomatous lesions.

Adrenal myelolipoma could occur together with adrenal adenoma as collision tumour in the adrenal gland. This is not surprising as these tumours are common tumours in adrenal gland. In the literature, approximately 20 cases have been documented (Caliumi et al. 2004, Ong et al. 2007, Lu et al. 2008, Yamada et al. 2011). Lu and coworkers analysed 17 cases reported in the literature and noted that they were often noted in females (male-to-female ratio = 1:3) and in the left adrenal gland (Lu et al. 2008). The myelolipomas noted in this setting was often small and with diameter ranged from 5 mm to 30 mm (Caliumi et al. 2004, Lu et al. 2008). Many of these are non-functional adenomas. There are some other lesions reported that could co-exist with adrenal myelolipoma such as ganglieneuroma, pheochromocytoma, hibernoma, etc. (Schwartz & Wasson 2003, Shenoy et al. 2015).

The genetic profile of adrenal myelolipoma is rarely mentioned. Chang and coworkers reported an adrenal myelolipoma with a chromosomal translocation (3;21) (q25;p11) (Chang et al. 2002). Similar change is noted in haematopoietic neoplasm reflecting that myelolipoma could derive from misplaced haematopoietic cells. Also, Bishop and coworkers have reported that eight of the 11 myelolipomas from female patients had non-random X-chromosome inactivation. These findings suggest clonal origin of myelolipoma (Bishop et al. 2006).

No malignant progression of adrenal myelolipoma has been reported. In the literature, the longest clinical follow-up reported in the literature was 12 years (Lam & Lo 2001). Managements of the large/symptomatic tumours are by surgery as large myelolipomas

### Table 2 Clinical and pathological features of adrenal lipomas in the literature.

<table>
<thead>
<tr>
<th>Author/year/country of publication</th>
<th>Sex</th>
<th>Side</th>
<th>Size/weight (mm/g)</th>
<th>Presentation</th>
<th>Imaging</th>
<th>Follow-up (year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lange/1966/Germany</td>
<td>M/54</td>
<td>Right</td>
<td>25/–</td>
<td>Paroxysmal hypertension</td>
<td>Not done</td>
<td>–</td>
</tr>
<tr>
<td>Prinz/1982/USA</td>
<td>F/73</td>
<td>Right</td>
<td>30/–</td>
<td>Incidental at CT</td>
<td>CT</td>
<td>–</td>
</tr>
<tr>
<td>Avinoach/1989/Israel</td>
<td>F/40</td>
<td>Right</td>
<td>13/7</td>
<td>Incidental at laparotomy</td>
<td>Not done</td>
<td>–</td>
</tr>
<tr>
<td>Lam/1997 and 2001/Hong Kong</td>
<td>M/78</td>
<td>Right</td>
<td>80/190</td>
<td>Incidental at US</td>
<td>US</td>
<td>7</td>
</tr>
<tr>
<td>Ghavamian/1998/USA</td>
<td>M/50</td>
<td>Left</td>
<td>80/80</td>
<td>Incidental in tuberculosis</td>
<td>CT</td>
<td>–</td>
</tr>
<tr>
<td>Sharma/1998/India</td>
<td>M/45</td>
<td>Right</td>
<td>120/225</td>
<td>Lumbar pain</td>
<td>US/CT</td>
<td>1</td>
</tr>
<tr>
<td>Büttner/1999/Germany</td>
<td>M/50</td>
<td>Right</td>
<td>11/–</td>
<td>Incidental at autopsy</td>
<td>Not done</td>
<td>–</td>
</tr>
<tr>
<td>Rodriguez-Calvo/2007/Spain</td>
<td>M/70</td>
<td>Left</td>
<td>10/–</td>
<td>Incidental at autopsy</td>
<td>Not done</td>
<td>–</td>
</tr>
<tr>
<td>Shumaker/2008/USA</td>
<td>M/68</td>
<td>Left</td>
<td>70/135</td>
<td>Left flank pain</td>
<td>CT/MRI</td>
<td>–</td>
</tr>
<tr>
<td>Gupta/2009/India</td>
<td>M/51</td>
<td>Right</td>
<td>90/–</td>
<td>Incidental at CT</td>
<td>CT</td>
<td>–</td>
</tr>
<tr>
<td>Shah/2009/Pakistan</td>
<td>M/35</td>
<td>Right</td>
<td>50/200</td>
<td>Abdominal pain/haematuria</td>
<td>US/CT</td>
<td>–</td>
</tr>
<tr>
<td>Singaporewalla/2009/Singapore</td>
<td>M/44</td>
<td>Left</td>
<td>156/–</td>
<td>Abdominal pain, CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Goldenberg/2011/USA</td>
<td>M/55</td>
<td>Right</td>
<td>70/–</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>–</td>
</tr>
<tr>
<td>Gunay/2011/Turkey</td>
<td>F/68</td>
<td>Left</td>
<td>70/–</td>
<td>Incidental at MRI</td>
<td>MRI</td>
<td>–</td>
</tr>
<tr>
<td>Kapetanakis/2011/Greece</td>
<td>F/54</td>
<td>Left</td>
<td>160/950</td>
<td>Postprandial pain</td>
<td>CT</td>
<td>6</td>
</tr>
<tr>
<td>Patel/2011/India</td>
<td>M/43</td>
<td>Right</td>
<td>150/810</td>
<td>Incidental at US</td>
<td>US/CT/MRI</td>
<td>0.3</td>
</tr>
<tr>
<td>Jain/2012/India</td>
<td>F/55</td>
<td>Right</td>
<td>120/–</td>
<td>Right flank pain</td>
<td>US/CT</td>
<td>–</td>
</tr>
<tr>
<td>Zhao/2014/China</td>
<td>F/31</td>
<td>Right</td>
<td>40/18</td>
<td>Incidental</td>
<td>NA</td>
<td>6.2</td>
</tr>
<tr>
<td>F/60</td>
<td>Right</td>
<td>100/172</td>
<td>Incidental</td>
<td>NA</td>
<td>4.6</td>
<td></td>
</tr>
<tr>
<td>F/51</td>
<td>Right</td>
<td>60/112</td>
<td>Back pain</td>
<td>NA</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>10F/14M</td>
<td>17 right/7 left</td>
<td>15 asymptomatic; 9 symptomatic</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Average</td>
<td>54</td>
<td>–</td>
<td>75/417</td>
<td>–</td>
<td>–</td>
<td>4.1</td>
</tr>
</tbody>
</table>

CT, computed tomography; MRI, magnetic resonance imaging; NA, not available; US, ultrasonography.
(such as measuring more than 60 mm) are prone to spontaneous rupture. Most of the centres worldwide do not operate for asymptomatic adrenal myelolipoma less than 40 mm in diameter (Shenoy et al. 2015).

**Adrenal lipoma**


The prevalence of the tumour is low, and there is no large series of adrenal lipoma in the literature. In 2001, Lam and Lo reported 3 cases in a 30-year period and adrenal lipoma accounted for 0.7% of the primary adrenal tumours (Lam & Lo 2001). In a more recent series, Zhao and coworkers reported 3 cases of adrenal lipoma in a 31-year period. They reported that the tumour accounted for 4% of all adrenal lipomatous tumours (Zhao et al. 2014).

In contrast to other adrenal lipomatous lesions, adrenal lipoma is more common in males. The female-to-male ratio is 0.7 to 1 (10 males and 14 females). Also, adrenal lipoma was found in patients in the sixth decade of life (mean age = 54; age range = 35–78). One-third of the reported cases were in this age group.

All the adrenal lipomas noted in the literature are non-functional. It is not surprising that majority of the cases were incidental findings either at autopsy or at radiological examination. There were 9 symptomatic cases as a result of the mechanic effect of the tumours. The case reported by Lange in 1966 showed paroxysmal hypertension, which is assumed to be due to mechanical irritation of the adrenal medulla to produce catecholamines. The symptomatic patients with adrenal lipoma presented with pain (Lange 1966).

Adrenal lipoma is more frequently noted on in the right adrenal gland (17 on the right; 7 on the left; right-to-left ratio = 2.4–1). In the literature, Milathianakis and coworkers reported a giant adrenal lipoma of 200 mm in dimension and 2900 g (Milathianakis et al. 2002). The mean maximum dimension of adrenal lipomas was 75 mm (range, 10–200 mm). Slightly over half (54%; 13/24) of the tumours noted in the literature were larger than 60 mm. Also, the mean weight of the adrenal gland with the tumour was 417 g (range, 7–2900). Apart from the giant adrenal lipoma reported by Milathianakis and coworkers, the other adrenal lipomas were less than 1000 g (Milathianakis et al. 2002).

Apart from detected at autopsy, the adrenal lipomas were often detected as incidentalomas on radiological examination. Ultrasonography of the abdomen showed a hyperechoic mass in the region of adrenal gland (Lam et al. 1997, Sharma et al. 1998, Milathianakis et al. 2002, Patel et al. 2011). Recently, Puri and coworkers have reported the use of endoscopic ultrasound-guided fine aspiration on a patient with adrenal lipoma (Puri et al. 2015). However, no detail information was reported in

---

**Figure 2**

Adrenal lipoma. (A) Adrenal lipoma composed of yellow homogenous fatty tissue encased by adrenal cortex. Note the adrenal gland at one end of the tumour. (B) Microscopic appearance of the adrenal lipoma showing that it is composed of mature adipose tissue with no bone marrow elements (haematoxylin and eosin × 1).
the case. Most often, adrenal lipoma was detected by computed tomography scan, which demonstrated a well-circumscribed, non-enhancing supra-renal mass of adipose tissue density. Magnetic resonance imaging was not often preformed and showed similar findings to those in computed tomography scan (Shumaker et al. 2008, Patel et al. 2011). Nevertheless, the diagnosis of adrenal lipoma could only be made on histological examination.

On macroscopic examination, the tumour is well demarcated and composed of yellow adipose tissue (Fig. 2A). Most of the tumours are yellow with homogenous and soft cut sections. However, patches of haemorrhages could be seen (Lam et al. 1997, Singaporewalla et al. 2009, Kapetanakis et al. 2011, Jain et al. 2012). In one case, the bleeding from the vessels in the lipoma resulted in retroperitoneal bleeding (Singaporewalla et al. 2009).

On microscopic examination, adrenal lipoma is composed of mature adipose tissue (Fig. 2B). Calcification was noted in 3 of the reported cases (Ghavamian et al. 1998, Lam & Lo 2001, Milathianakis et al. 2002).

---

**Table 3** Clinical and pathological features of adrenal teratoma in the literature.

<table>
<thead>
<tr>
<th>Author/year of publication/country of publication</th>
<th>Sex/age</th>
<th>Side</th>
<th>Size/weight (mm/g)</th>
<th>Presentation</th>
<th>Imaging</th>
<th>Follow-up</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lam/1999/Hong Kong</td>
<td>F/18</td>
<td>Left</td>
<td>110/67</td>
<td>Back pain</td>
<td>CT</td>
<td>7 years</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/17</td>
<td>Right</td>
<td>75/74</td>
<td>Back pain</td>
<td>CT/MRI</td>
<td>1 year</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>F/37</td>
<td>Left</td>
<td>100/–</td>
<td>Back pain</td>
<td>CT</td>
<td>8 year</td>
<td>–</td>
</tr>
<tr>
<td>Kaneko/1998/Japan</td>
<td>M/46</td>
<td>Right</td>
<td>90/–</td>
<td>Abdominal mass</td>
<td>US/CT/MRI</td>
<td>–</td>
<td>Labelled as dermoid cyst</td>
</tr>
<tr>
<td></td>
<td>F/8</td>
<td>Right</td>
<td>60/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>F/57</td>
<td>Left</td>
<td>80/200</td>
<td>Abdominal pain</td>
<td>CT/MRI</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>F/21</td>
<td>Left</td>
<td>380/10,000</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/77</td>
<td>Left</td>
<td>170/–</td>
<td>Asymptomatic</td>
<td>XR/US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/8</td>
<td>Right</td>
<td>80/–</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>3 year</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>F/61</td>
<td>Left</td>
<td>80/54</td>
<td>Asymptomatic</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/new born</td>
<td>Right</td>
<td>140/–</td>
<td>Respiratory distress</td>
<td>US/CT/MRI</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>James/2009/USA</td>
<td>M/45 days</td>
<td>Left</td>
<td>55/–</td>
<td>Mass in antenal US</td>
<td>US/MRI</td>
<td>1 year</td>
<td>Increased serum AFP</td>
</tr>
<tr>
<td>Oguzkurt/2009/Turkey</td>
<td>M/40</td>
<td>Right</td>
<td>90/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>6 months</td>
<td>With neurocytoma</td>
</tr>
<tr>
<td></td>
<td>M/8</td>
<td>Right</td>
<td>100/–</td>
<td>Abdominal pain</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Shrestha/2010/Nepal</td>
<td>M/38</td>
<td>Left</td>
<td>38/267</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/4</td>
<td>Left</td>
<td>30/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ciftci/2013/Turkey</td>
<td>M/3 months</td>
<td>Left</td>
<td>83/–</td>
<td>Abdominal distension</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Bhatti/2013/Saudi Arabia</td>
<td>M/22</td>
<td>Left</td>
<td>100/484</td>
<td>Left flank pain</td>
<td>CT</td>
<td>6 months</td>
<td>–</td>
</tr>
<tr>
<td>Tang/2014/China</td>
<td>M/39</td>
<td>Right</td>
<td>225/1620</td>
<td>Hypertension</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Zhao/2014/Hong Kong</td>
<td>F/21</td>
<td>Right</td>
<td>60/48.5</td>
<td>Back pain</td>
<td>US/CT</td>
<td>6.7 years</td>
<td>–</td>
</tr>
<tr>
<td>Mardi/2015/India</td>
<td>F/24</td>
<td>Left</td>
<td>190/–</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>1.5 years</td>
<td>Complete colon wall seen</td>
</tr>
<tr>
<td>Li/2015a/China</td>
<td>M/49</td>
<td>Right</td>
<td>110/–</td>
<td>Abdominal mass</td>
<td>US/CT</td>
<td>8 months</td>
<td>–</td>
</tr>
<tr>
<td>Li/2015b/China</td>
<td>F/21</td>
<td>Right</td>
<td>85/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>&amp;/16</td>
<td>Right</td>
<td>90/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>&amp;/43</td>
<td>Left</td>
<td>49/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>&amp;/49</td>
<td>Left</td>
<td>52/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>F/51</td>
<td>Right</td>
<td>24/–</td>
<td>Asymptomatic</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Nadeem/2015/Pakistan</td>
<td>M/19</td>
<td>Right</td>
<td>80/–</td>
<td>Lumbar pain</td>
<td>CT</td>
<td>1 year</td>
<td>–</td>
</tr>
<tr>
<td>Ratkal/2015/India</td>
<td>F/29</td>
<td>Right</td>
<td>100/130</td>
<td>Abdominal pain</td>
<td>US/CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Bhatia/2016/India</td>
<td>F/24</td>
<td>Left</td>
<td>24/–</td>
<td>Abdominal pain/cough US/CT</td>
<td>–</td>
<td>Rupture and involves lung</td>
<td></td>
</tr>
<tr>
<td>Narla/2016/India</td>
<td>F/2</td>
<td>Right</td>
<td>60/–</td>
<td>Abdominal pain</td>
<td>MRI</td>
<td>–</td>
<td>With carcinoid</td>
</tr>
<tr>
<td>Total</td>
<td>21F:11M</td>
<td>60/–</td>
<td>Abdominal pain</td>
<td>–</td>
<td>20 symptomatic/12 asymptomatic</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Average</td>
<td>27 years</td>
<td>–</td>
<td>99/1189</td>
<td>–</td>
<td>–</td>
<td>2.8 years</td>
<td>–</td>
</tr>
</tbody>
</table>

CT, computed tomography; F, female; g, gram; L, left; M, male; MRI, magnetic resonance imaging; R, right; US, ultrasonography; XR, abdominal X-ray; –, not available.
Chronic inflammatory cells (Kapetanakis et al. 2011) were found in a case having symptoms for 10 years. Also, a case had active inflammation and abscess as a result of adjacent infection as a result of percutaneous nephrolithotomy (Gupta et al. 2009). In addition, a case had necrosis, which is related to co-existing tuberculosis (Ghavamian et al. 1998).

The main differential diagnosis of adrenal lipoma is myelolipoma, which is much more common in incidence. The only feature that differentiates lipoma from myelolipoma is the absence of myeloid elements in the adrenal lipoma. Thus, adequate tissue blocks should be sampled from non-fatty areas such as haemorrhagic region or calcified areas to rule out the presence of myeloid elements.

Of the 24 adrenal lipomas in the literature, 6 were detected at autopsy and 18 were detected at examination of surgical resected specimens. In the latter group, 5 were operated by laparoscopic approach and 13 by open surgery. Adrenal lipoma is a benign tumour.

In the literature, clinical follow-up was identified in 39% (7 of the 18) of the patients underwent surgery. The longest clinical follow-up of the lesion documented was 7 years (Lam & Lo 2001). None of the tumours had local recurrence or signs of malignancy on clinical follow-up.

In summary, adrenal lipoma is rare. The diagnosis could only be possible on surgical removed specimen. It is a benign lesion. However, it could be symptomatic and presented with pain as a result of complications.

Adrenal teratoma


![Figure 3](http://erc.endocrinology-journals.org/cgi/content/fig/16/3/ERC-16-0564/F6)

**Figure 3**

Adrenal teratoma. (A) The age distribution of adrenal mature teratoma showing the tumour is more common in the age groups (0–9) as well (20–29). (B) CT scan showing a well-demarcated heterogeneous mass in the left adrenal region. (C) Macroscopic appearance showing the tumour is composed of large amount of fatty tissue. (D) Microscopic appearance showing the presence of cartilage as well as adipose tissue (haematoxylin and eosin x 20).
Adrenal teratoma was first reported by Lam and Lo in 1999 (Lam & Lo 1999). In a 30-year study period, the authors have reported 3 adrenal teratomas. The adrenal teratomas accounted for 1.3% of the surgical resected primary adrenal tumours and 0.7% of all primary adrenal tumours (Lam & Lo 2001). In 2014, Zhou and coworkers in their 31-year study showed 2 adrenal teratomas, which comprised 2.7% of adrenal lipomatous tumours (Zhao et al. 2014). The other large series was by Li and coworkers who reported 5 adrenal teratomas and the prevalence of the lesion in adrenal diseases in a 5-year period is 0.13% (Li et al. 2015b).

The majority of the adrenal teratomas were reported in Asian populations. Other than these, a few cases were reported in United States of America (USA) (n=3), Chile (n=2) and Spain (n=1). In the cases noted in Asian populations, half of the reported cases (48%; 15/31) were reported from Chinese patients from Hong Kong or China. The other patients were from India (n=4), Nepal (n=1), Pakistan (n=1), South Korea (n=1) and Japan (n=1). Also, there are three cases reported from Turkey and one case from Saudi Arabia.

Adrenal teratoma was more common in females with female-to-male ratio = 1.9–1 (21 females; 11 males). From the pooled data in literature, adrenal teratoma occurs in a wide age range with the median age at presentation at 23 years. There is bimodal age distribution for the cases (Fig. 3A). The tumours are common in the first decade as well as the third decade of life. There is no gender difference in the age distribution.

Slightly over 60% (20 of 32; 62.5%) of the patients with adrenal teratoma were symptomatic. The most common symptom is abdominal pain (n=14). Other clinical presentations noted include abdominal distension and hypertension. A case was noted in a new born boy in respiratory distress (James et al. 2009). Bhatia and coworkers reported an adrenal teratoma complicated by extension through diaphragm and involving the lung giving the symptom of coughing (Bhatia et al. 2016). All the cases are non-functional on biochemical investigations. Oguzkurt and coworkers have reported an adrenal teratoma with increase serum alpha fetoprotein level in a 45-day-old infant (Oguzkurt et al. 2009). However, no immature element was noted on histology.

CT or MRI had been performed in all the patients with adrenal teratomas reported in the literature. The examination showed mainly a fatty mass as in other adrenal lipomatous tumours. However, when compared to other adrenal lipomatous tumours, adrenal teratomas were often cystic, heterogeneous and commonly having calcification (Fig. 3B). From the pooled data in literature with detailed descriptions, 90% (26 of 29) of adrenal teratomas were cystic and 76% (22 of 29) showed calcification. The typical radiological features of adrenal teratoma are heterogeneous mass in the adrenal region containing fluid, adipose tissue and/or serum in the form of a fat-fluid level and with calcification. Pre-operative diagnosis of adrenal teratoma was made in four (13%) adrenal teratomas (Li et al. 2015a, Mardi et al. 2015, Nadeem et al., 2015).

Adrenal teratoma has no side preponderance (right = 17; left = 15). From the pooled data in the literature, the mean maximum dimension of the tumour is 99 mm (range, 24–380 mm). Eighty-four percent (27 of 32) of the reported cases were of diameter 60 mm or above. A giant adrenal teratoma was reported by Polo and coworkers, which weighed 10 kg (Polo et al. 2004). The other tumours weighed between 48.5 g and 1620 g. On cut sections, adrenal teratoma was often cystic. Greasy sebaceous material, skin and hair are commonly noted. In addition, it may be composed of large mass of adipose tissue mimicking other fatty tumours such as myelolipoma and lipoma (Lam & Lo 1999) (Fig. 3C). In some instances, cartilage, bone and teeth as well as mucinous substance could be noted on macroscopic examination (Shrestha & Lalchan 2010, Nadeem et al. 2015).

On histological examination, all cases were mature teratoma. Characteristically, they are mostly cystic and contain tissues from 3 germ layers (Fig. 3D). Mardi and coworkers noted a case with complete layers of colon wall (Mardi et al. 2015). No evidence of immature elements or malignancy noted. Erosoz described a case in an 8-year-old boy with co-existing neurocytoma (Erosoz et al. 2011). Also, Narla and coworkers noted an adrenal teratoma associated with carcinoma in a 2-year-old girl (Narla et al. 2016).

Teratomas are result of abnormal development of pluripotent cells: embryonic cells or germ cells. Teratomas of embryonic origin are congenital. For instance, 3 adrenal teratomas occurred in young infants; one antenatal, one at birth and one at 3 months of age (James et al. 2009, Oguzkurt et al. 2009, Ciftci et al. 2013). Teratomas of germ cell origin could be congenital or in adult. The close anatomic association of adrenal cortex with the urogenital apparatus and its embryological development from coelomic epithelium make it a possible site of development of teratoma.
The main differential diagnosis of adrenal teratoma was to differentiate it from retroperitoneal teratoma. It is often difficult and many of the cases reported in the literature actually mentioned clearly that it is not possible to differentiate the teratoma arising in these two sites. The finding of normal adrenal cortex encasing the tumour could be the most important sign of adrenal teratoma. The other possible differential diagnosis is metastatic malignant teratoma. A case of malignant teratoma presented with adrenal mass has been reported (McMillan & Horwich 1987).

In the literature, 19 of the 32 cases had follow-up information. The clinical follow-up of patients with adrenal teratoma ranged from half a year to 8 years (mean = 2.7 years). None of the patients had recurrent or malignant change.

**Adrenal angiomyolipoma**

Angiomyolipoma is a member of the family of neoplasms that derive from perivascular epitheloid cells (PEC) (PEComa family) (Thway & Fisher 2015). It could occur in the settings of tuberous sclerosis complex. Lymphangioleiomyomatosis (LAM) is as an infrequent symptomatic pulmonary complication in tuberous sclerosis (Hancock et al. 2002). It also belongs to the PEComa family. Angiomyolipoma is a tumour composed of blood vessels, smooth muscle (myo) cells and fat cells. The tumour is positive for melanocytic (HMB-45 and melan-A) and smooth muscle marker (smooth muscle actin). It most often occurs in the kidney or liver.

Adrenal angiomyolipoma is very rare. Because of the anatomical location, it is difficult to distinguish between primary renal and primary adrenal angiomyolipoma on radiological examination. A total

<table>
<thead>
<tr>
<th>Author/year/country of publication</th>
<th>Sex/age</th>
<th>Side</th>
<th>Size/weight (mm/g)</th>
<th>Presentation</th>
<th>Syn.</th>
<th>Imaging</th>
<th>FU (year)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lam/2001/HK</td>
<td>F/46</td>
<td>Left</td>
<td>80/115</td>
<td>Incidental at CT</td>
<td>CT</td>
<td>CT</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/20</td>
<td>Left</td>
<td>2/3</td>
<td>Incidental at nephrectomy</td>
<td>TS</td>
<td>–</td>
<td>8</td>
<td>AML in kidney and liver</td>
</tr>
<tr>
<td>Elsayes/2005/USA</td>
<td>F/49</td>
<td>Right</td>
<td>122/–</td>
<td>Incidental at CT</td>
<td>TS</td>
<td>CT/MRI</td>
<td>–</td>
<td>AML in left kidney</td>
</tr>
<tr>
<td>Godara/2007/India</td>
<td>F/45</td>
<td>Left</td>
<td>150/–</td>
<td>Epigastric discomfort</td>
<td>CT</td>
<td>–</td>
<td>1.5</td>
<td>–</td>
</tr>
<tr>
<td>Sutter/2007/Switzerland</td>
<td>F/32</td>
<td>Right</td>
<td>90/–</td>
<td>Abdominal pain</td>
<td>LAM</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>D’Antonio/2009/Italy</td>
<td>M/42</td>
<td>Left</td>
<td>60/100</td>
<td>Back pain, anaemia, fever</td>
<td>CT/MRI</td>
<td>1</td>
<td>Epitheloid type</td>
<td></td>
</tr>
<tr>
<td>Chee Kong/2010/Malaysia</td>
<td>M/61</td>
<td>Left</td>
<td>100/–</td>
<td>Left loin pain</td>
<td>CT</td>
<td>–</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Yener/2011/Turkey</td>
<td>F/45</td>
<td>Right</td>
<td>50/–</td>
<td>Epigastric discomfort</td>
<td>US/CT</td>
<td>0.25</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Hu/2012/China</td>
<td>F/55</td>
<td>Right</td>
<td>160/–</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>–</td>
<td>0.50</td>
<td>–</td>
</tr>
<tr>
<td>Hafeez Bhatti/2012/Pakistan</td>
<td>F/72</td>
<td>Right</td>
<td>90/–</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Sazuka/2013/Japan</td>
<td>F/68</td>
<td>Right</td>
<td>66/–</td>
<td>Back pain</td>
<td>CT/MRI/PET</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Goswami/2014/India</td>
<td>F/43</td>
<td>Right</td>
<td>95/–</td>
<td>Right flank pain</td>
<td>CT</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Zhao/2014/China</td>
<td>F/47</td>
<td>Left</td>
<td>60/45</td>
<td>Asymptomatic</td>
<td>CT/MRI</td>
<td>6.20</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>M/70</td>
<td>Left</td>
<td>80/121</td>
<td>Asymptomatic</td>
<td>CT/MRI</td>
<td>5.40</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Li/2015/China</td>
<td>M/53</td>
<td>Left</td>
<td>90/–</td>
<td>Abdominal pain</td>
<td>CT/PET</td>
<td>8</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Kwazneski li/2016/USA</td>
<td>F/65</td>
<td>Right</td>
<td>65/626</td>
<td>Abdominal pain</td>
<td>US/CT</td>
<td>3</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>11F/5M</td>
<td>–</td>
<td>88/168</td>
<td>11 symptomatic/ asymomatic</td>
<td>–</td>
<td>–</td>
<td>3.30</td>
<td>–</td>
</tr>
</tbody>
</table>

AML, angiomyolipoma; CT, computed tomography; F, female; FU, follow-up; LAM, lymphangioleiomyomatosis; M, male; MRI, magnetic resonance imaging; PET, positron emission tomography; Syn., syndrome associated; TS, tuberous sclerosis; US, ultrasonography; –, not available.

Figure 4
Adrenal angiomyolipoma. Microscopic appearance of the adrenal angiomyolipoma showing the presence of blood vessels and myxoid cells in additional to the adipose tissue (haematoxylin and eosin × 20).
of 16 well-documented cases have been noted in the literature (Table 4) (Lam & Lo 2001, Elsayes et al. 2005, Godara et al. 2007, Sutter et al. 2007, D’Antonio et al. 2009, Chee Kong et al. 2010, Yener et al. 2011, Hu & Xi 2012, Haeez Bhatti et al. 2013, Sazuka et al. 2013, Goswami et al. 2014, Zhao et al. 2014, Li et al. 2015a,b, Kwazneski et al. 2016). Most of the cases (12 of 16; 75%) were reported in Asia.

Lam and Lo first documented the histology of 2 adrenal angiomyolipoma in the literature in 2001 (Lam & Lo 2001). Both cases were asymptomatic. In the report, angiomyolipoma accounted for 0.5% and 0.8% of the primary and surgical resected primary adrenal tumours, respectively. On the other hand, most of the reported cases in the literature were symptomatic (69%; n = 11) and presented with abdominal pain.

### Table 5 Clinical and pathological features of other adrenal tumours with component of adipose tissue in the literature.

<table>
<thead>
<tr>
<th>Author/year/country</th>
<th>Diagnosis</th>
<th>Sex/age</th>
<th>Side</th>
<th>Size/weight (mm/g)</th>
<th>Presentation</th>
<th>Imaging</th>
<th>FU (years)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lam/2001/Hong Kong</td>
<td>Liposarcoma</td>
<td>F/36</td>
<td>Right</td>
<td>180/783</td>
<td>Right loin pain</td>
<td>CT/MRI</td>
<td>2</td>
<td>Detected at pregnancy, cystic</td>
</tr>
<tr>
<td>Zhao/2014/China</td>
<td>Liposarcoma</td>
<td>F/31</td>
<td>Right</td>
<td>123/1250</td>
<td>Right back pain</td>
<td>CT/MRI</td>
<td>7.4</td>
<td>–</td>
</tr>
<tr>
<td>Schwartz/2003/USA</td>
<td>Hibernoma</td>
<td>F/42</td>
<td>Right</td>
<td>11/–</td>
<td>Incidental pain</td>
<td>CT</td>
<td>–</td>
<td>Had myelolipoma</td>
</tr>
<tr>
<td>Fernando Val-</td>
<td>Hibernoma</td>
<td>F/55</td>
<td>Left</td>
<td>17/75</td>
<td>Incidental pain</td>
<td>CT</td>
<td>–</td>
<td>Had adenoma</td>
</tr>
<tr>
<td>Bernali/2013/Spain</td>
<td>Adenoma with fat</td>
<td>M/47</td>
<td>Left</td>
<td>40/–</td>
<td>Abdominal pain</td>
<td>CT/MRI</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Sato/1995/Japan</td>
<td>Adenoma with fat</td>
<td>F/46</td>
<td>Right</td>
<td>100/270</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>1/4</td>
<td>Pre-clinical Cushing</td>
</tr>
<tr>
<td>Papotti/1996/Italy</td>
<td>Adenoma with fat</td>
<td>F/74</td>
<td>Left</td>
<td>65/50</td>
<td>Abdominal pain</td>
<td>US/US</td>
<td>0.5</td>
<td>Pre-clinical Cushing, HCC</td>
</tr>
<tr>
<td>Feldberg/1996/Israel</td>
<td>Adenoma with fat</td>
<td>F/40</td>
<td>Left</td>
<td>80/–</td>
<td>Lumbar pain</td>
<td>CT/US/MRI</td>
<td>2</td>
<td>–</td>
</tr>
<tr>
<td>Uriev/2014/Israel</td>
<td>Adenoma with fat</td>
<td>F/51</td>
<td>Left</td>
<td>40/18</td>
<td>Cushing</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mylarapp/2014/India</td>
<td>Adenoma with fat</td>
<td>F/12</td>
<td>Right</td>
<td>100/–</td>
<td>Hirsutism</td>
<td>CT/US</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Luo/2015/China</td>
<td>Adenoma with fat</td>
<td>M/46</td>
<td>Right</td>
<td>20/8</td>
<td>Abdominal pain</td>
<td>CT</td>
<td>–</td>
<td>Non-functional adenoma</td>
</tr>
<tr>
<td>Montone/2009/USA</td>
<td>Cortical neoplasm UMP with fat</td>
<td>F/50</td>
<td>Left</td>
<td>55/105</td>
<td>Incidental</td>
<td>CT</td>
<td>–</td>
<td>Myelolipomatous metaplasia</td>
</tr>
<tr>
<td>Cortical neoplasm</td>
<td>UMP with fat</td>
<td>F/56</td>
<td>Right</td>
<td>110/249</td>
<td>Abdominal pain</td>
<td>MRI</td>
<td>–</td>
<td>Myelolipomatous metaplasia</td>
</tr>
<tr>
<td>Lin/1998/USA</td>
<td>Oncocytoma with fat</td>
<td>F/68</td>
<td>Left</td>
<td>80/–</td>
<td>Abdominal pain</td>
<td>–</td>
<td>5 1/3</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Oncocytoma with fat</td>
<td>F/41</td>
<td>Left</td>
<td>75/85</td>
<td>Incidental</td>
<td>–</td>
<td>8.25</td>
<td>–</td>
</tr>
<tr>
<td>Rosenkrantz/2010/</td>
<td>Oncocytoma with fat</td>
<td>M/52</td>
<td>Right</td>
<td>90/294</td>
<td>Abdominal pain</td>
<td>Incidental</td>
<td>CT/MRI</td>
<td>3</td>
</tr>
<tr>
<td>USA</td>
<td>Oncocytoma with fat</td>
<td>M/52</td>
<td>Left</td>
<td>85/182</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Izumi/2003/Japan</td>
<td>ACC with fat (myxoid)</td>
<td>M/38</td>
<td>Left</td>
<td>135/380</td>
<td>Hypertension</td>
<td>CT/MRI</td>
<td>–</td>
<td>Increased cortical hormones</td>
</tr>
<tr>
<td>Heye/2005/Belgium</td>
<td>ACC with fat</td>
<td>M/38</td>
<td>Left</td>
<td>70/145</td>
<td>Hypertension</td>
<td>US/MRI</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Egbert/2010/USA</td>
<td>ACC with fat</td>
<td>M/41</td>
<td>Left</td>
<td>220/–</td>
<td>Abdominal pain</td>
<td>CT/MRI</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Termote/2007/</td>
<td>Cavernous hemangioma with fat</td>
<td>M/73</td>
<td>Left</td>
<td>80/182</td>
<td>Incidental</td>
<td>CT/MRI</td>
<td>–</td>
<td>Calcification present</td>
</tr>
<tr>
<td>Belgium</td>
<td>Pheochromocytoma with lipid</td>
<td>M/27</td>
<td>Right</td>
<td>30/–</td>
<td>Headaches</td>
<td>CT</td>
<td>–</td>
<td>Bilateral pheochromocytoma</td>
</tr>
</tbody>
</table>

ACC, adrenocortical carcinoma; CT, computed tomography; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; NA, not available; UMP, uncertain malignant potential; US, ultrasonography.
By analysing the features of well-documented cases in the English literature, adrenal angiomyolipoma was more common in females (11 females, 5 males; female-to-male ratio = 2.2:1). The tumours were noted in a wide age range from 20 to 72. The mean age at presentation was 51 years with 43% (n = 7) of the cases first noted in the fifth decades of life. It has no site predilection (8 on the right side and 8 on the left side).

In a study of 209 patients with renal angiomyolipomas, 11% (n = 24) had tuberous sclerosis (likely or definite) (Lane et al. 2008). Similarly, of the 16 adrenal angiomyolipomas noted in the literature, 2 had tuberous sclerosis and 1 had lymphangioleiomyomatosis; giving a 19% prevalence of syndrome complex in adrenal angiomyolipomas. There is an additional case of adrenal angiomyolipoma noted in a series of extra-thoracic lymphangioleiomyomatosis (Maziak et al. 1996). However, no detail information was given about the case and thus this case was not counted in the current analysis.

Radiologically, the tumour appeared heterogeneous with fat and haemorrhagic component mimicking myelolipoma (Sazuka et al. 2013). It can also be misdiagnosed as adrenocortical tumour (Godara et al. 2007, Yener et al. 2011, Ku & Xi 2012).

On pathological examination, the dimension of the tumours ranges from 2 mm to 160 mm (mean = 88 mm) and the weight of the tumours range from 3 to 626 g (mean = 168 g). The histological features of most of the tumours noted in the literature are classical with mixture of the 3 components: vessels, muscles and adipose tissue (Fig. 4). Calcification was documented in 2 cases (Hafeez Bhatti et al. 2013, Kwazneski et al. 2016). Also, one of the cases has epithelioid morphology (D’Antonio et al. 2009).

All the cases reported to date are benign on morphological examination. Over a short mean follow-up period of 3.3 years, all the cases showed no tumour recurrence or metastases.

### Other adrenal lipomatous tumours

The other lipomatous tumours in the adrenal gland are rare. They could be divided into 3 groups; rare primary adrenal lipomatous tumours, adrenocortical tumours with fat component and adrenal tumours with fat component (Table 5).

### Rare primary lipomatous tumours

The rare primary adrenal lipomatous tumours are liposarcoma and hibernoma.

Liposarcoma is the most common retroperitoneal sarcoma. There are four major liposarcoma subtypes: atypical lipomatous tumour/well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid/round cell liposarcoma and pleomorphic liposarcoma (Matthyssens et al. 2015). It is very difficult to differentiate whether the liposarcoma is primary in the adrenal or in the soft tissue in the peritoneum. In the literature, two adrenal liposarcomas have been reported (Lam & Lo 2001, Zhao et al. 2014). They were noted in female patients in the fourth decade of life. Also, both adrenal liposarcomas were myxoid (round cell) liposarcoma. It is worth noting that retroperitoneal liposarcoma are most often of well-differentiated subtype or dedifferentiated liposarcoma (Matthyssens et al. 2015).

Hibernoma is a tumour composed of brown fat. Histologically, the tumour is composed of primitive embryonal fat characterized by multi-vacuolated

<table>
<thead>
<tr>
<th>Table 6</th>
<th>Comparison of the major type of fatty tumours in the adrenal gland.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parameters</td>
<td>Myelolipoma</td>
</tr>
<tr>
<td>Proportion of surgically resected adrenal tumour (%)</td>
<td>3</td>
</tr>
<tr>
<td>No of cases reported</td>
<td>&gt;1200</td>
</tr>
<tr>
<td></td>
<td>adrenal cortical tumour</td>
</tr>
<tr>
<td>Female-to-male ratio</td>
<td>1.4–1</td>
</tr>
<tr>
<td>Age (mean/range) (year)</td>
<td>53 (1.3–84)</td>
</tr>
<tr>
<td>Side (right-to-left ratio)</td>
<td>2.1–1</td>
</tr>
<tr>
<td>Size (mean/range) (mm)</td>
<td>63 (4–400)</td>
</tr>
<tr>
<td>Weight (g)</td>
<td>49 (4–6000)</td>
</tr>
<tr>
<td>Diseases association</td>
<td>Chronic diseases</td>
</tr>
<tr>
<td>Symptomatic/asymptomatic</td>
<td>1.6–1</td>
</tr>
</tbody>
</table>
fat cells containing phosphatides in the cytoplasm and eccentrically placed nuclei. Two cases of adrenal hibernomas were reported in the English literature. The first case of adrenal hibernoma was reported by Schwartz and Wasson in 2003 (Schwartz & Wasson 2003). The tumour was associated with myelolipoma. The other case was reported by Val-Bernal and coworkers in 2013 (Val-Bernal et al. 2013). The patient also had a cortical adenoma producing primary hyperaldosteronism. Both are small tumours (11 mm and 17 mm, respectively), asymptomatic and detected in associated with other benign adrenal tumours.

Adrenocortical tumours with fat component

Adrenal cortical adenoma is the most common tumour in the adrenal gland (Lam 1992). Myelolipomatous changes are common. On the other hand, lipomatous changes without bone marrow component are not frequently reported. Seven adrenal cortical adenomas with extensive area of adipose tissue have been described in the literature. They have been labelled as adrenal cortical adenoma with fat component (Sato et al. 1995), adenoma with lipomatous metaplasia (Papotti et al. 1996), adrenal cortical extensive fat cell metaplasia (Feldberg et al. 1996) and lipoadenoma (Mylarappa et al. 2014, Uriev et al. 2014, Luo et al. 2015). In addition, Montone and coworkers have reported 2 cases of adrenocortical neoplasm with uncertain malignant potential having separate areas of myelolipomatous and lipomatous metaplasia (Montone et al. 2009). Similar to conventional adenomas, majority of these tumours were reported in female patients; only 2 cases were reported in male patients.

Adrenal oncocytoma is an adrenal cortical tumour consisting entirely or predominately of cells with dense eosinophilic cytoplasm. Four cases have been reported to contain fat. They were benign on clinical follow-up (Lin et al. 1998, Rosenkrantz et al. 2010). Two of these cases were asymptomatic and two presented with abdominal pain.

There are 3 adrenocortical carcinoma reported to be having a component of adipose tissue (Izumi et al. 2003, Heye et al. 2005, Egbert et al. 2010). The tumours were noted in left adrenal, functional and in male patients. One of them is a myxoid variant of adrenocortical carcinoma (Izumi et al. 2003).

Other primary adrenal tumours with fat component

Fat have been reported in cavernous haemangioma (Termote et al. 2007) and pheochromocytoma (Ramsay et al. 1987).

Conclusion

Adrenal lipomatous tumour is uncommon. Myelolipomas is the predominant type but various types of lipomatous adrenal gland tumours such as lipomas, teratoma, angiomyolipoma, and so forth are increasingly being reported. This group of tumours are often benign and non-functional. Table 6 presented the key features of the common adrenal lipomatous tumours showing that there are subtle differences between them. Surgery is recommended for tumours that are symptomatic, hormonally active and presenting with complications. It is important to recognize the features of this group of lipomatous tumours in the adrenal gland as they are being detected on increasing incidence as a result of the wide-spread use of modern imaging modalities.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


Bishop E, Eble JN, Cheng L, Wang M, Chase DR, Orazi A & O’Malley DP 2006 Adrenal myelolipomas show nonrandom X-chromosome...


Lipomatous tumours in adrenal gland

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.

http://erc.endocrinology.journals.org

Review

A K-y Lam

Lipomatous tumours in adrenal gland

24:3 R78

2015

Endocrine-Related Cancer

2016.3.272

Endocrine-Related Cancer

DOI: 10.1530/ERC-16-0564

2017 Society for Endocrinology

Published by Bioscientifica Ltd.


Ulrev L, Maslovsky I, Ben-Dor D & Barak F 2014 Adrenal lipoadenoma. Pathology Diagnosis 2 2. (doi:10.7243/2052-7896-2-2)


